Výsledky vyhledávání - "Marek K. Kania"

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer

Autor: Cathy Eng, Caly Chien, James C. Yao, Takayuki Yoshino, Zhao Yang, Josep Tabernero, Alberto Sobrero, William Schelman, Marek K. Kania, Arvind Dasari

Publikováno v: Scientia

Fruquintinib, a novel, highly selective, small-molecule tyrosine kinase inhibitor of VEGF receptors (VEGFRs)-1, -2 and -3, is approved in China for the treatment of metastatic colorectal cancer. FRESCO-2, a global, randomized, double-blind, placebo-c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f97826b262eaeeda6c251300f40e7a0
https://pubmed.ncbi.nlm.nih.gov/33993740

Zobrazit plný text záznamu

Surufatinib in U.S. patients with soft tissue sarcoma

Autor: Sujana Movva, Alexander I. Spira, Erika P. Hamilton, Judy S. Wang, Allen Lee Cohn, James F. Strauss, Silvia Stacchiotti, Chris Tucci, John Kauh, Shivani Nanda, Marek K. Kania, Shreyaskumar Patel

Publikováno v: Journal of Clinical Oncology. 40:11557-11557

11557 Background: Surufatinib is an inhibitor of VEGFR1, 2, & 3, FGFR1, and CSF-1R. A manageable safety profile, and statistically significant improvement in progression-free survival (PFS) in patients (pts) treated with surufatinib have previously b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18b6767139fc32c12c1260d03b98331c
https://doi.org/10.1200/jco.2022.40.16_suppl.11557

Zobrazit plný text záznamu

Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer

Autor: Arvind Dasari, Joleen M. Hubbard, Cathy Eng, Heather Yeckes-Rodin, Stacey M Ukrainskyj, Zhao Yang, William R. Schelman, Marek K. Kania, Tanios S. Bekaii-Saab

Publikováno v: Journal of Clinical Oncology. 40:93-93

93 Background: Fruquintinib (F) is a highly selective, novel, oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3. The phase (Ph) 3 FRESCO study (NCT02314819) that investigated F (5mg daily, 3 w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ce733b0288d4aa4cf755eeb1ac2145f
https://doi.org/10.1200/jco.2022.40.4_suppl.093

Zobrazit plný text záznamu

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

Autor: Mark Rudinski, Zhao Yang, Vijayvel Jayaprakash, Anu Doraiswamy, Farhad Ravandi, Marjo Hahka-Kemppinen, Marek K. Kania

Publikováno v: Blood. 138:4438-4438

Background: Isocitrate dehydrogenase (IDH) is a rate-limiting tricarboxylic acid cycle enzyme with 3 isoforms. Mutations in IDH1 and IDH2 result in gain-of-function activity that can result in tumor formation and/or progression and have been associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45e775d6aae599bbd51707fd6c065c8f
https://doi.org/10.1182/blood-2021-145636

Zobrazit plný text záznamu

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Autor: Paolo Strati, Mark Rudinski, Rathi Pillai, Michał Taszner, Dominik Chraniuk, Caly Chien, Shivani Nanda, Marek K. Kania, Eva González-Barca, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen

Publikováno v: Blood. 138:2432-2432

Background: Spleen tyrosine kinase (Syk) plays an integral role in B-cell receptor signaling critical in the development and survival of several subtypes of lymphoma. HMPL-523 is a selective, oral Syk inhibitor that has shown strong anti-tumor effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f635679e1464a45026a51c347037ed0b
https://doi.org/10.1182/blood-2021-145641

Zobrazit plný text záznamu

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors

Autor: John S. Kauh, Shivani Nanda, Andrew Scott Paulson, Arvind Dasari, Marek K. Kania, Jennifer W Carlisle, Christopher Tucci

Publikováno v: Journal of Clinical Oncology. 39:TPS2677-TPS2677

TPS2677 Background: Surufatinib (S) is an inhibitor of VEGFR1, 2, & 3; FGFR1; and CSF-1R. In two phase 3 randomized trials (SANET-ep; NCT02588170 & SANET-p; NCT02589821) S demonstrated a manageable safety profile and statistically significant efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04b844ee980487c7530df99f920b051c
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2677

Zobrazit plný text záznamu

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)

Autor: Shivani Nanda, Daneng Li, Christopher Tucci, Arvind Dasari, Andrew Scott Paulson, Max W. Sung, Marek K. Kania, John S. Kauh

Publikováno v: Journal of Clinical Oncology. 39:4114-4114

4114 Background: Surufatinib (S) is a targeted inhibitor of tyrosine kinases VEGFR1, 2, and 3; FGFR1; and CSF-1R. A manageable safety profile and statistically significant efficacy of S have previously been demonstrated in patients (pts) with advance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7ca4af7e215aa8082692dbcec983d9c
https://doi.org/10.1200/jco.2021.39.15_suppl.4114

Zobrazit plný text záznamu

A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations

Autor: Filip Janku, Zhao Yang, John S. Kauh, Marek K. Kania, Olatunji B. Alese, Christopher Tucci

Publikováno v: Journal of Clinical Oncology. 39:TPS3159-TPS3159

TPS3159 Background: Isocitrate dehydrogenase (IDH) is a rate-limiting tricarboxylic acid cycle enzyme with 3 isoforms. Mutations in IDH1 and IDH2 result in gain-of-function activity that can cause tumor formation and/or progression and have been asso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::774950c616da9e0b456edfd2ce567de4
https://doi.org/10.1200/jco.2021.39.15_suppl.tps3159

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání